Amgen and Novartis are set to commercially launch the first calcitonin gene-related peptide (CGRP) receptor inhibitor in the U.S. next week following FDA approval yesterday of the companies’ co-marketed migraine prevention treatment Aimovig™ (erenumab).
Aimovig will be the first-and-only monoclonal antibody specifically designed to prevent migraines by blocking the CGRP receptor believed to play a causal role in migraine pathophysiology. Aimovig has been projected by Evaluate Pharma to generate about $475 million in sales by 2022.
Aimovig is expected to be available to patients in the U.S. within a week, Amgen and Novartis said.
“We look forward to working closely with Amgen in the U.S. to bring this treatment to physicians and their patients, who could now gain days of their lives back each month,” Paul Hudson, CEO of Novartis Pharmaceuticals, said in a statement.
In Europe, the European Medicines Agency (EMA) is reviewing a ...